Form 4: Monopar Therapeutics COO Reports Stock Transaction
Insider Transaction (Form 4)
Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, reported multiple transactions in common stock on September 30, 2026.
Summary
- Option exercise/conversion: acquired 4,384 Common Stock on September 30, 2026; holds 59,998 after (Direct).
- Tax/exercise-price withholding: disposed of 1,944 Common Stock at $79.67 ($154,878) on September 30, 2026; holds 58,054 after (Direct).
- Option exercise/conversion: disposed of 4,384 Restricted Stock Unit on September 30, 2026; holds 35,115 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Andrew Cittadine — Officer (Chief Operating Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-30 | Option exercise/conversion | Common Stock | 4,384 | — | — | 59,998 |
| 2026-09-30 | Tax/exercise-price withholding | Common Stock | 1,944 | $80 | $154.9K | 58,054 |
| 2026-09-30 | Option exercise/conversion | Restricted Stock Unit | 4,384 | — | — | 35,115 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Option exercise/conversion (4,384 shares) |
| 2026-09-30 | Tax/exercise-price withholding (1,944 shares) |
| 2026-09-30 | Option exercise/conversion (4,384 shares) |
Keywords
insider transaction, Form 4, MNPR, Monopar Therapeutics, neutral, Andrew Cittadine
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.